Abstract 1581P
Background
Navya-AI is a clinically validated digital intervention that outputs patient-specific, evidence-based information; with 97% concordance between Navya-AI output and expert recommendations, and 80% adoption of recommendations by patients. Given high financial toxicity of suboptimal maintenance treatments in OC, use of AI to encourage optimal treatment has potential benefit. This study assesses the impact of Navya-AI in improving compliance to guidelines for genomic testing for women with OC in India; especially since generics for genomic testing and PARP inhibitors are cost effectively accessible in India.
Methods
Since March 2022, genomic testing for BRCA1/2 and HRD has been a recommended guideline for stage III & IV OC by NCCN, ESMO, and NCG India. From March 2022 to March 2024, all women with OC who received a Navya-AI enabled review of their treatment plan were prospectively analyzed for concordance on genomic testing and precision care. Intervention with Navya AI was used to close any identified care gaps.
Results
Of 260 OC patients who received a Navya-AI review, 80% [209/260] met guideline criteria for genomic testing. Stage I/II [47], and rare histologies [4] were excluded. Women were diverse with respect to age (years) [0-35: 6%, 35-50: 30%, 51-65: 49%, >65: 15%]; stage [III 42%, IV: 58%]; family history of cancer: 24%. Genomic testing and precision care was planned for only 30% [63/209] of the patients. In the remaining 70% [146/209], digital intervention by Navya-AI including information on the risks/benefits of genomic testing, potential use of PARP inhibitors, importance of cascade genetics, and patient navigation to their treating oncologists enabled guidelines compliance.
Conclusions
Guideline compliant care is a useful metric in tracking quality of care in gynecologic cancers, where wide care disparities exist. Positive findings on genomic testing in OC has a significant impact on progression-free survival and decreasing cancer burden. More than 60% of patients presenting to a nationally used digital health expert opinion service in India would have missed such critical testing. Through AI driven technologies, this disparity can be identified and closed, globally.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1563P - Increasing the earlier detection of lung cancer: A toolbox for change
Presenter: Helena Wilcox
Session: Poster session 10
1564P - Limited participation in breast cancer screening among low-SES women: A matter of engagement or of health literacy?
Presenter: Allegra Ferrari
Session: Poster session 10
1566P - Optimizing participation in lung cancer screening program: Results from the first round in ILYAD study in Lyon University Hospital
Presenter: Emmanuel Grolleau
Session: Poster session 10
1567P - Physicians' adenoma detection rate and the risk of colorectal cancer in sequential screening programs: An observational cohort study
Presenter: Li Xie
Session: Poster session 10
1568P - Challenges in pilot lung cancer screening in Vojvodina, Serbia
Presenter: Jelena Djekic Malbasa
Session: Poster session 10
1569P - Secondary delay in breast cancer diagnosis and role of rural medical practitioners: A cause and cure finding study
Presenter: Rahul Agarwal
Session: Poster session 10
1570P - Factors and impacts of delayed presentation for county-level patients with breast cancer in a real-life setting in China
Presenter: Yinghua Ji
Session: Poster session 10
1571P - The reasons that motivate a change of specialties among oncology residents
Presenter: Christophe Ducrocq
Session: Poster session 10
1572P - Factors associated with career choice in oncology among medical students
Presenter: Nicolas Penel
Session: Poster session 10